Page 103 - Haematologica July

CHD4 is required for maintenance of childhood acute myeloid leukemia
35. Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta- analysis of the prognostic value of genes. BMC Med Genomics. 2009;2:18.
36. Bagger FO, Sasivarevic D, Sohi SH, et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 2016;44(D1):D917-924.
37. Bohm M, Wachtel M, Marques JG, et al. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhab- domyosarcoma. J Clin Invest. 2016; 126(11):4237-4249.
38. Chudnovsky Y, Kim D, Zheng S, et al. ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblas- toma tumor-initiating cell state. Cell Rep. 2014;6(2):313-324.
39. Guillemette S, Serra RW, Peng M, et al. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remod- eling factor CHD4. Genes Dev. 2015;29(5): 489-494.
40. Somervaille TC, Cleary ML. PU.1 and Junb: suppressing the formation of acute myeloid
leukemia stem cells. Cancer Cell. 2006;
10(6):456-457.
41. Cong L, Ran FA, Cox D, et al. Multiplex
genome engineering using CRISPR/Cas
systems. Science. 2013;339(6121):819-823. 42. Billerbeck E, Barry WT, Mu K, Dorner M, Rice CM, Ploss A. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin- 3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood. 2011;117(11):
3076-3086.
43. Subramanian A, Tamayo P, Mootha VK, et
al. Gene set enrichment analysis: a knowl- edge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
44. Prasad P, Lennartsson A, Ekwall K. The roles of SNF2/SWI2 nucleosome remodel- ing enzymes in blood cell differentiation and leukemia. Biomed Res Int. 2015; 2015:347571.
45. Yoshida T, Hazan I, Zhang J, et al. The role of the chromatin remodeler Mi-2beta in hematopoietic stem cell self-renewal and
multilineage differentiation. Genes Dev.
2008;22(9):1174-1189.
46. Mohd-Sarip A, Teeuwssen M, Bot AG, et
al. DOC1-dependent recruitment of NURD reveals antagonism with SWI/SNF during epithelial-mesenchymal transition in oral cancer cells. Cell Rep. 2017;20(1):61-75.
47. Nio K, Yamashita T, Okada H, et al. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma. J Hepatol. 2015;63(5):1164-1172.
48. Buddaseth S, Gottmann W, Blasczyk R, Huyton T. Dysregulation of cell cycle con- trol caused by overexpression of the onco- gene pp32r1 (ANP32C) and the Tyr>His mutant pp32r1Y140H. Biochim Biophys Acta. 2013;1833(5):1212-1221.
49. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pen- tadecadeoxynucleotide targeted against c- myc mRNA. Proc Natl Acad Sci USA. 1988; 85(4):1028-1032.
haematologica | 2018; 103(7)
1181